References
- Kessler RC, Berglund P, Demler O, Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602
- Kessler RC, Chiu WT, Demler O, Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-627
- de Graaf R, Bijl RV, Smit F, Risk factors for 12-month comorbidity of mood, anxiety, and substance use disorders: findings from the Netherlands Mental Health Survey and Incidence Study. Am J Psychiatry 2002;159:620-629
- Kessler RC, Berglund P, Demler O, The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-3105
- DuPont RL, Rice DP, Miller LS, Economic costs of anxiety disorders. Anxiety 1996;2:167-172
- Greenberg PE, Sisitsky T, Kessler RC, The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 1999;60:427-435
- Wang PS, Aguilar-Gaxiola S, Alonso J, Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the WHO world mental health surveys. Lancet 2007;370:841-850
- Wang PS, Lane M, Olfson M, Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:629-640
- Konnopka A, Leichsenring F, Leibing E, Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: a systematic review. J Affect Disord 2009;114:14-31
- Stein MB, Cantrell CR, Sokol MC, Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. Psychiatr Serv 2006;57:673-680
- McLaughlin TP, Khandker RK, Kruzikas DT, Overlap of anxiety and depression in a managed care population: Prevalence and association with resource utilization. J Clin Psychiatry 2006;67:1187-1193
- Charlson ME, Pompei P, Ales KL, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383
- OECD. Country statistical profiles 2009: United States. 2009 [updated 2009; cited 2009 November 30]; Available from: http://stats.oecd.org/index.aspx?queryid=18175
- Blough DK, Ramsey SD. Using Generalized Linear Models to Assess Medical Care Costs. Health Services and Outcomes Research Methodology 2000;1:185-202
- Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461-494
- Norberg MM, Calamari JE, Cohen RJ, Quality of life in obsessive-compulsive disorder: an evaluation of impairment and a preliminary analysis of the ameliorating effects of treatment. Depress Anxiety 2008;25:248-259
- Schultz LT, Heimberg RG, Rodebaugh TL, The appraisal of social concerns scale: psychometric validation with a clinical sample of patients with social anxiety disorder. Behav Ther 2006;37:392-405
- Lipsitz JD, Schneier FR. Social phobia. Epidemiology and cost of illness. Pharmacoeconomics 2000;18:23-32
- Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry 2006;51:9-91S
- Simon GE, Chisholm D, Treglia M, Course of depression, health services costs, and work productivity in an international primary care study. Gen Hosp Psychiatry 2002;24:328-335
- Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety 2008;25:72-90
- Marciniak MD, Lage MJ, Dunayevich E, The cost of treating anxiety: the medical and demographic correlates that impact total medical costs. Depress Anxiety 2005;21:178-184
- Zhu B, Zhao Z, Ye W, The cost of comorbid depression and pain for individuals diagnosed with generalized anxiety disorder. J Nerv Ment Dis 2009;197:136-139